News
Public · Published
Guggenheim maintains Tenet Healthcare at Buy, lowers price target to $306 from $307
Guggenheim kept its Buy rating on Tenet Healthcare and lowered its price target to $306 from $307, a 0.3% decrease. The new target implies 13.1% upside from the October 29 close of $270.57.
Published:
Updated:
What happened
Guggenheim kept its Buy rating on Tenet Healthcare and lowered its price target to $306 from $307, a 0.3% decrease. The new target implies 13.1% upside from the October 29 close of $270.57.
Confirmed
Global impact / market context
A price target is the analyst's estimate of where a stock could trade, so a slightly lower target signals modestly reduced expectations while the Buy rating still suggests the analyst sees Tenet shares as undervalued relative to that estimate.
Analyst inference
The target sits 13.1% above the October 29 close, meaning the analyst expects gains even after the small cut. Investors watching Tenet can compare this estimate with their own view of the hospital operator's earnings and cash flow.
Analyst inference
What to watch
- Guggenheim's Buy rating and $306 target, which implies 13.1% upside from the October 29 close of $270.57, remain the key published figures for Tenet Healthcare. Confirmed
- Watch whether other analysts revise their own Tenet ratings or price targets, which would show whether Guggenheim's modestly lower target reflects a broader change in expectations. Proposed
- Track Tenet's upcoming earnings and hospital admissions data, since weaker patient volumes or higher costs could pressure profit per sale and push the shares away from the $306 target. Analyst inference
Evidence
- Original source link unavailable